Unorthodox long-term aerosolized ampicillin use for methicillin-susceptible staphylococcus aureus lung infection in a cystic fibrosis patient

Pediatric Pulmonology

Volumn 44, Issue 5, 2009, Pages 512-515

  Maiz, Luis ^a   Lamas, Adelaida ^a   Fernandez Olmos, Ana ^b   Suarez, Lucrecia ^a   Canton, Rafael ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hospital RamcSn y Cajal   (Spain)

Author keywords

Aerosolized ampicillin; Cystic fibrosis; Staphylococcus aureus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOTAXIME; CEFTAZIDIME; CLOXACILLIN; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; GOBEMICINA; IBUPROFEN; LEVOFLOXACIN; LINEZOLID; METHYLPREDNISOLONE; MINOCYCLINE; SALBUTAMOL; TEICOPLANIN; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANAMNESIS; ARTICLE; BRONCHOSPASM; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; FEMALE; GENOTYPE; HUMAN; LONG TERM CARE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PULSED FIELD GEL ELECTROPHORESIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; AMPICILLIN; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TIME;

EID: 66749136864     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20983     Document Type: Article

References (21)

1. Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence? Pediatr Pulmonol 2005;40:471 -476.
2. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8:1594-1604.
3. Stone A, Saiman L. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med 2007;13:515 -521.
4. Wong K, Roberts MC, Owens L, Fife M, Smith AL. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol 1984;17:113-1139.
5. Kahl BC, Duebbers A, Lubritz G, Haeberle J, Koch HG, Ritzerfeld B, Reilly M, Harms E, Proctor RA, Herrmann M, Peters G. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol 2003;41:4424-4427.
6. UK Cystic Fibrosis Trust Antibiotic Group. Antibiotic treatment for cystic fibrosis: report of the UK Cystic Fibrosis Trust Antibiotic Group, 2nd edition, Bromley, Kent, UK: UK Cystic Fibrosis Trust Antibiotic Group; 2002.
7. di Sant'Agnese PA, Andersen DH. Celiac syndrome. IV. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am J Dis Child 1946;72:17-61.
8. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981;2:1137-1139.
9. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987;81:272-279.
10. Hill SL, Morrison HM, Burnett D, Stockley RA. Short-term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses or by inhalation. Thorax 1986;41:559-565.
11. Jensen T, Pedersen SS, Garne S, Heilmann C, H0iby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831 -838.
12. Steinkamp G, Tummler B, Gappa M, Albus A, Potel J, Doring G, von der Hardt H. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6:91 -98.
13. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, Wentz K, Smith AL. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746.
14. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW. Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutic Network. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009;154:183-188.
15. Maiz L, Canton R, Mir N, Baquero F, Escobar H. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 1998;26:287-289.
16. Solis A, Brown D, Hughes J, Van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003;36:189-195.
17. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey BW. Cystic Fibrosis Therapeutic Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841 -849.
18. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J. Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith J. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
19. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-1196.
20. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219-226.
21. Morosini MI, Garcia-Castillo M, Loza E, Perez- Vazquez M, Baquero F, Canton R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis: use of high range Etest strips. J Clin Microbiol 2005;43:4480-4485.